← 返回

工程化 NK 细胞阻断实体瘤中的免疫代谢 CD73-腺苷轴

英文原题:Engineered natural killer cells impede the immunometabolic CD73-adenosine axis in solid tumors.

查看英文原题

Engineered natural killer cells impede the immunometabolic CD73-adenosine axis in solid tumors.

PubMed 2022/07/11(内容时间) Elife N/A(JCR 2025)

分数与星级只用于站内排序 —— 不代表疗效、安全性或个人适用性。

中文摘要

CD73(由5′-核苷酸外切酶基因NT5E编码)产生的腺苷引发免疫代谢重编程,是实体瘤中公认的免疫抑制机制,并促进免疫逃逸。腺苷不仅会促进肿瘤进展,还会特异性导致包括自然杀伤(NK)细胞在内的免疫细胞功能障碍。本研究对人NK细胞进行工程化改造,使其直接靶向CD73-腺苷轴并阻断CD73酶活性。工程化NK细胞不仅在非小细胞肺癌模型中抑制癌细胞缺氧摄取ATP驱动的腺苷能代谢,还能通过特异性识别过表达的CD73介导肿瘤细胞杀伤。由此形成一种“单药”免疫疗法,结合了抗体特异性、嘌呤能信号阻断以及NK细胞介导的靶细胞杀伤。我们还显示,靶向CD73的NK细胞在体内具有强效作用,可抑制肿瘤,同时促进NK细胞浸润CD73阳性肿瘤并增强肿瘤内NK细胞活化。

展开英文摘要原文

Immunometabolic reprogramming due to adenosine produced by CD73 (encoded by the 5'-ectonucleotidase gene NT5E ) is a recognized immunosuppressive mechanism contributing to immune evasion in solid tumors. Adenosine is not only known to contribute to tumor progression, but it has specific roles in driving dysfunction of immune cells, including natural killer (NK) cells.

Here, we engineered human NK cells to directly target the CD73-adenosine axis by blocking the enzymatic activity of CD73. In doing so, the engineered NK cells not only impaired adenosinergic metabolism driven by the hypoxic uptake of ATP by cancer cells in a model of non-small-cell lung cancer, but also mediated killing of tumor cells due to the specific recognition of overexpressed CD73. This resulted in a 'single agent' immunotherapy that combines antibody specificity, blockade of purinergic signaling, and killing of targets mediated by NK cells.

We also showed that CD73-targeted NK cells are potent in vivo and result in tumor arrest, while promoting NK cell infiltration into CD73 + tumors and enhancing intratumoral activation.

论文信息

作者
Chambers AM、Lupo KB、Wang J、Cao J、Utturkar S、Lanman N、Bernal-Crespo V、Jalal S
单位
Department of Industrial and Physical Pharmacy, Purdue University West Lafayette, West Lafayette, United States.United States
文献类型
非美国政府资助研究 · 美国 NIH 资助研究
期刊
eLife2022 Jul 11
原文标识
PubMed 35815945 · DOI 10.7554/eLife.73699